Deutsche Bank AG Sells 377,813 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Deutsche Bank AG trimmed its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 65.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 200,395 shares of the biopharmaceutical company's stock after selling 377,813 shares during the quarter. Deutsche Bank AG owned 0.17% of Catalyst Pharmaceuticals worth $4,182,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth $27,000. Farther Finance Advisors LLC raised its stake in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth $65,000. KBC Group NV raised its stake in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after purchasing an additional 1,542 shares during the period. Finally, Quarry LP bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter worth $104,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,000 shares of the company's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the sale, the insider now directly owns 68,873 shares in the company, valued at $1,627,468.99. This represents a 38.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 351,879 shares of company stock worth $8,214,815. Company insiders own 10.40% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CPRX shares. Stephens reiterated an "overweight" rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Wall Street Zen upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Robert W. Baird lifted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $32.29.

Catalyst Pharmaceuticals Stock Down 0.9%

Catalyst Pharmaceuticals stock traded down $0.21 during midday trading on Thursday, reaching $24.11. The stock had a trading volume of 912,598 shares, compared to its average volume of 1,105,894. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.75 and a 12 month high of $26.16. The firm's 50-day moving average price is $23.49 and its 200 day moving average price is $22.54. The firm has a market capitalization of $2.94 billion, a PE ratio of 20.43, a P/E/G ratio of 3.31 and a beta of 0.70.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.